简体中文 | 繁體中文 | English

Asia-Pacific Region Key Focus of DIA 45th Annual Meeting, June 21-25 in San Diego

2009-04-28 08:32
  • zh_cn
  • zh_hant
  • en

HORSHAM, Pa.--(BUSINESS WIRE)--Global drug development is a key focus of the Drug Information Association (DIA) 45th Annual Meeting. Biotech and pharmaceutical industry attendees gain insights into information critical to advancement of drug discovery and lifecycle management as well as global regulatory issues.

The DIA 45th Annual Meeting provides the only opportunity for attendees to speak face-to-face with representatives from more than 30 international regulatory agencies, including:

  • Australia Therapeutic Goods Administration
  • China State Food and Drug Administration (SFDA)
  • India Directorate of Drugs Control
  • Japan Pharmaceuticals and Medical Devices Agency (PMDA)
  • Taiwan Center for Drug Evaluation
  • Korean Food and Drug Administration
  • Korean Ministry for Health, Welfare and Family Affairs
  • Taiwan Department of Health
  • Vietnam Ministry of Health

“This global concentration brings together the top international regulators, academics, patient groups, and industry professionals,” explains Program Committee Member Ling Su, Ph.D., and vice president, clinical research and development, Asia Pacific, Wyeth Pharmaceutical Co., Ltd., China. “DIA’s Annual Meeting provides a neutral forum to share experiences and perspectives on global drug development.”

Sessions on issues affecting the Asia-Pacific region:

“We strive to advance regulatory science through educational programs and information exchange,” says PMDA Chief Executive Tatsuya Kondo, M.D, Ph.D. “DIA is vital to this strategy.”

The Multi-track Plenary Session (June 22, 3:30-5:00 pm), Improving Safety with Every Step: Pillars of the Pharmaceutical Landscape, brings together representatives from industry, regulatory agencies, academia and patient groups to share perspectives on how to enhance patient safety.

About the Drug Information Association (DIA)

The Drug Information Association (DIA) serves more than 30,000 professionals from regulatory agencies, academia, and the biopharmaceutical industry worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for exchange of information critical to the advancement of drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based board of directors and executive management team. Visit www.diahome.org or call 215-442-6100.

 

Contacts

Drug Information Association
Joe Krasowski, 215-293-5812
Joe.Krasowski@diahome.org
or
Bonnie Shaw, 858-724-2500
Bonnie@clearpointagency.com